[SCHEDULE 13G/A] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

BlackRock Portfolio Management LLC filed Amendment No. 1 to Schedule 13G for Stoke Therapeutics, Inc. (STOK) dated 30 June 2025. The filing discloses that BlackRock’s reporting business units now beneficially own 2,550,341 common shares, representing 4.7 % of outstanding stock. Because the position is < 5 %, the firm is reporting under Rule 13d-1(b) as a passive institutional investor.

The shares are held with sole voting power over 2,412,388 shares and sole dispositive power over the full 2,550,341 shares; there is no shared voting or dispositive authority. BlackRock confirms the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. Item 5 expressly states that BlackRock’s ownership has fallen to 5 % or less of the class, triggering the amended filing.

While BlackRock remains a meaningful holder, the reduction below the 5 % threshold removes it from the list of “5 % owners” in future proxy statements and may slightly reduce perceived institutional sponsorship. No other financial metrics, transactions, or strategic actions are disclosed in this filing.

Insights

Institutional Ownership Analyst

TL;DR: BlackRock cut STOK to 4.7 %, filing 13G/A as passive holder; impact is modest and largely technical.

BlackRock’s amended 13G shows its aggregated business units now hold 2.55 million STOK shares, down to 4.7 % of the float. Dropping below the 5 % line ends 13D-level scrutiny and signals a modest reduction in commitment, but BlackRock still owns a sizable block with full voting and dispositive control. For investors, the filing is chiefly informative: no intent to influence control, and no sale mandate is implied. Liquidity pressure appears limited because the residual stake remains intact; however, the market could interpret the sub-5 % level as waning institutional enthusiasm. Overall, the disclosure is routine with limited market impact.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Stoke Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

86150R107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

BlackRock Portfolio Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,412,388.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,550,341.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,550,341.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Stoke Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 45 WIGGINS AVENUE BEDFORD MA 01730
Item 2.
(a)	Name of person filing: BlackRock Portfolio Management LLC In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock Portfolio Management LLC, 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 86150R107
Item 4.	Ownership
(a)	Amount beneficially owned: 2550341
(b)	Percent of class: 4.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2412388
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2550341
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Stoke Therapeutics, Inc.. No one person's interest in the common stock of Stoke Therapeutics, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock Portfolio Management LLC

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/15/2025

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7